25-Jan-15The Chinese pharmaceutical sector saw lower growth in 2014 due to a host of challenges including slowing overall economic growth, regulatory shakeups, cost containment measures and price cuts, as well as healthcare reform turbulence. However, the market is still estimated to have grown 13% in 2014, to reach USD200 billion. [image: My Jungle Blog]

For more about China's healthcare sector, request our free 20-page whitepaper: China Healthcare Market Opportunities

09-Jan-15 The China Food and Drug Administration (CFDA) plans to allow online sales of prescription drugs soon. If approved, the policy could seed a market worth more than USD160 billion as sales shift from hospitals to online platforms such as Alibaba and JD.com. [image: Reuters/Stringer]

31-Dec-14 There's been a lot going on in emerging markets in 2014. Here's a look back at 12 notable Medtech and Healthcare growth markets stories that you may have missed, month-by-month, including "Indonesia’s new national health insurance scheme", "Korea to nurture medical device industry", "Turkey’s pharma market is ripe for profit", "China healthcare draws investors" and more.

14-Jan-15 Overall, the Chinese government created lots of space for the private sector in 2014, meaning demand remained strong and companies benefited. This trend is likely to continue in 2015, especially if initiatives such as online drug sales, foreign participation in health services, and more funding for doctors’ pay, CFDA and telemedicine, are continued. [image: Forbes]

09-Jan-15 While drug makers say local regulators are ill-equipped and inadequately staffed to monitor them, the watchdogs in turn hold state governments responsible for failing to strengthen the supervisory mechanism. "The governments were in a mad rush to attract investments by creating tax havens but did not pay enough attention to… quality standards," a state drug controller said, admitting inadequacies in the system. [image: The Economic Times / BCCL]